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Seminars in Nin the human kidney, with ET-1 being the predominant isoform. ET-1 and ET-2 bind to two G-protein–coupled
receptors, ETA and ETB, whereas at physiological concentrations ET-3 has little affinity for the ETA receptor.
The human kidney is unusual among the peripheral organs in expressing a high density of ETB. The renal
vascular endothelium only expresses the ETB subtype and ET-1 acts in an autocrine or paracrine manner to
release vasodilators. Endothelial ETB in kidney, as well as liver and lungs, also has a critical role in scavenging
ET-1 from the plasma. The third major function is ET-1 activation of ETB in in the nephron to reduce salt and
water re-absorption. In contrast, ETA predominate on smooth muscle, causing vasoconstriction and mediating
many of the pathophysiological actions of ET-1. The role of the two receptors has been delineated using highly
selective ETA (BQ123, TAK-044) and ETB (BQ788) peptide antagonists. Nonpeptide antagonists, bosentan,
macitentan, and ambrisentan, that are either mixed ETA/ETB antagonists or display ETA selectivity, have been
approved for clinical use but to date are limited to pulmonary hypertension. Ambrisentan is in clinical trials in
patients with type 2 diabetic nephropathy. This review summarizes ET-receptor antagonism in the human
kidney, and considers the relative merits of selective versus nonselective antagonism in renal disease.
Semin Nephrol 35:125-136 C 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Keywords: Ambrisentan, antagonist, bosentan, endothelin-1, macitentan, sitaxentanAll three members of the endothelin (ET) familyof peptides, ET-1, ET-2, and ET-3, areexpressed in the human kidney, although ET-
1 is the predominant isoform. ET-1 and ET-2 bind to two
G-protein–coupled receptors, ETA and ETB, whereas at
physiological concentrations ET-3 has little afﬁnity for the
ETA receptor. The endothelin receptors are members of the
Family A G-protein–coupled receptors, a class of proteins
that has been exploited very successfully as targets for the
development of drugs.
The human kidney is unusual among the peripheral
organs in expressing a high density of ETB. The renal
vascular endothelium only expresses the ETB subtype
and ET-1 acts in an autocrine or paracrine manner to
release vasodilators. Endothelial ETB in kidney, as well
as liver and lungs, has a critical role in scavenging ET-
1 from the plasma. The third major function is for ET-1
activation of ETB in medullary epithelial cells to
reduce salt and water reabsorption. ETA predominatesee front matter
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ephrology, Vol 35, No 2, March 2015, pp 125–136on the vasculature to cause vasoconstriction. The
pathophysiological actions of ET-1 are mediated
mainly via the ETA subtype. The role of the two
subtypes has been delineated in preclinical and acute
experimental studies using highly selective ETA
(including BQ123, TAK-044) and ETB (BQ788) pep-
tide antagonists. Three nonpeptide antagonists, bosen-
tan, macitentan, and ambrisentan, that are either mixed
ETA/ETB antagonists or display ETA selectivity, have
been approved for clinical use, primarily in pulmonary
arterial hypertension.
In renal pathophysiological conditions ET-1 contrib-
utes to vascular remodeling, proliferation of mesangial
cells, and extracellular matrix production, mainly
through binding to ETA. Beneﬁcial actions of ET-1 on
sodium and water regulation mainly are ETB-mediated.
These ﬁndings suggest an ETA-selective antagonist
would have a therapeutic advantage over a mixed
antagonist in renal disease. Acute studies directly
comparing mixed and selective peptide antagonists
suggest selective ETA blockade, however, sparing ETB
may be beneﬁcial. However, this was balanced by a
greater prevalence of side effects for small-molecule,
orally active ETA antagonists compared with mixed
antagonists, although the latter also have their limita-
tions. The ET signaling pathway in the kidney remains a
promising clinical target for receptor antagonism, which
may be realized by the next generation of antagonists.ET RECEPTORS
The ET family comprises three isoforms, ET-1, ET-2,
and ET-3.1,2 Although messenger RNA encoding all
three has been detected in human kidney, ET-1 is the
predominant intrarenal isoform.3 ETs interact with two125
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Figure 1. Model of the ET-1 signaling pathway in the renal vasculature. The primary source of ET-1 production is
the vascular endothelium, although it also is produced by other cell types in the kidney including epithelial cells.
ET-1 is synthesized within the secretory vesicles of the constitutive pathway. Pro–ET-1 is processed to big ET-1 by
the action of a furin convertase. Big ET-1 then is transformed to the mature, biologically active peptide ET-1, mainly
through the action of ECE-1, although a second related enzyme, ECE-2, also may play a role, particularly under
acidic pathophysiological conditions. ET-1 also is released from Weibel-Palade bodies of the regulated pathway in
response to external stimuli. ET-1 released abluminally causes the underlying smooth muscle to contract, mainly
via ETA. The ligand-receptor complex then undergoes internalization to the endosome before recycling of the
receptor to the cell surface. Some smooth muscle cells from specific vascular beds express a low density of ETB,
but ETA antagonists are able to fully reverse an established ET-1 constrictor response, implying a minimal
contribution. Binding to endothelial ETB elicits an opposing vasodilatation via the release of relaxing factors as well
as removal of ET-1 from the circulation by internalization to the lysosome and degradation.
J.J. Maguire and A.P. Davenport126distinct G-protein–coupled receptors, ETA
4 and ETB
5
(Fig. 1), which were identiﬁed 2 years after the
discovery of the endogenous peptides in 1988. They
are both class A, G-protein–coupled receptors; this
class is the target of nearly half of currently available
medicines. This has resulted from well-developed
medicinal chemistry strategies and high-throughput
screening programs to identify small-molecule drugs,
stimulating considerable effort to discover ET-receptor
antagonists. The initial clue to the existence of two
subtypes and the key to classifying the receptors was
that ET-1 and ET-2 are equipotent at the ETA subtype
whereas ET-3 shows at least 100-fold lower potency
and at physiological concentration ET-3 is unlikely to
activate this subtype (Table 1). All three ETs bind to
ETB with similar afﬁnity.
6,7 This review focuses on the
role of ET receptors in the human kidney and considers
the clinical pharmacology of ET antagonists that havebeen used to block these receptors. The effects of ET-1
on the kidney are complex and more detailed informa-
tion can be found in reviews on renal endothelin
physiology8 and pathology,9 and the pharmacology
of the endothelin signaling pathway.10,11NO EVIDENCE FOR FURTHER ET-RECEPTOR
SUBTYPES
Further receptor subclassiﬁcations have been proposed
including suggestions that ETB could be subdivided into
ETB1, present on endothelial cells, and ETB2 on smooth
muscle cells, but there currently is no evidence that the
receptors expressed by these two cell types can be
distinguished pharmacologically.10,11 ET-receptor antago-
nists have not been successful in certain conditions such as
heart failure,12 perhaps implying that ETs may mediate
Table 1. Key ET Agonists and Antagonists Used in Research and Clinical Studies (Including Only Those Approved for Clinical
Use in Clinical Studies), and the Functional Role of Renal ET Receptors
ETA ETA/ETA ETB
Potency ET-1 ¼ ET-2 4 ET-3 ET-1 ¼ ET-2 ¼ ET-3
Peptide agonists Sarafotoxin S6C
BQ3020
IRL1620
Peptide antagonists BQ123 BQ788
FR139317
Tak-044
Clinically approved antagonists
Selective Sitaxentan
Ambrisentan
Mixed Bosentan
Macitentan
Renal Function ETA ETB
Vasculature Cortical vasoconstriction Medullary vasodilatation
Conduit vessel vasoconstriction Conduit vessel vasodilatation
Afferent arteriolar constriction Afferent arteriolar dilatation
Efferent arteriolar constriction Efferent arteriolar dilatation
Glomerulus Mesangial cell contraction
Mesangial cell proliferation
Podocyte injury
Epithelium Endothelial function not known
Inner medullary Extracellular matrix accumulation Natriuresis
collecting duct Interstitial fibrosis
Possible natriuresis
Endothelin-receptor antagonists 127their actions via previously unsuspected receptors;
however, this is unlikely. Following the sequencing of
the human genome, it is accepted that all genes that
potentially encode a G-protein–coupled receptor have
been identiﬁed and currently are classiﬁed as ‘orphan’ to
indicate that their endogenous ligand is not yet
known.13,14 These remaining orphan receptors (approx-
imately 80) have been screened against more than 20 ET
peptides (including all three endogenous isoforms and
their corresponding big ET precursors, C-terminal
metabolites, the ETA antagonist BQ123, and the ETB
agonist BQ3020) without detectable binding. The screen
also included two of the most closely related orphan
receptors to ETA and ETB, GPR37 (also known as
endothelin-receptor type B-like receptor or Parkin-
associated endothelin receptor-like receptor) and its
related receptor GPR37L1. Two neuropeptides, prosap-
tide and prosaposin, that are structurally distinct from
the ETs have been suggested to be the endogenous
ligands for GPR37 and GPR37L1.15PEPTIDE AGONISTS
Experimental medicine studies in volunteers mainly use
ET-1 that is equipotent for ETA and ETB (Table 1). ET-3,
which is modestly selective for ETB,
7 also has been usedbut greater ETB selectivity is shown by sarafotoxin S6c,
one of the isoforms originally identiﬁed from snake
venom.16 IRL1620 (Suc-[Glu9,Ala11,15]-endothelin-18-21)
17
is a truncated linear analogue in which the N-terminus has
an N-succinyl modiﬁcation, reducing metabolism by non-
speciﬁc peptidases. It was developed as an ETB agonist but
now is used in clinical trials as a potential vasodilator in the
delivery of anticancer agents and in neuroprotection where
it is known as SPI-1620 (licensed by Spectrum Pharma-
ceuticals, Henderson, NV). The second widely used ETB
agonist is BQ3020 ([Ala11,15]Ac-ET-l6-21),
18 however, this
compound has not been used clinically.PEPTIDE ANTAGONISTS
The ﬁrst endothelin-receptor antagonists to be discovered
were from natural product screening, compound libraries,
or drug design based on the structure of the endogenous ET
peptides (Table 1). The most widely used, according to the
number of published articles, is the cyclic pentapeptide BQ-
123 (D-Asp-L-Pro-D-Val-L-Leu-D-Trp-) (Ihara et al19),
based on peptides isolated from Streptomyces misakiensis,
a highly selective competitive ETA antagonist with low
nanomolar afﬁnity for the receptor. The second most
widely used is FR 139317 (N-[(hexahydro-1-azepinyl)
carbonyl]L-Leu[1-Me]D-Trp-3 [2-pyridyl]-D-Ala),20 a
J.J. Maguire and A.P. Davenport128linear tripeptide. These are both highly ETA selective for
human (as well as rodent) ET receptors and at concen-
trations used in experimental medicine or in vivo animal
experiments are likely to block only the ETA receptor; data
from these studies can be interpreted with conﬁdence.
TAK-044 is a cyclic hexapeptide also isolated from S
misakiensis with a more modest degree of ETA selectiv-
ity.21 BQ788 (N-[([2R,6S]-2,6-dimethyl-1-piperidinyl)car-
bonyl]-4-methyl-L-leucyl-N-[(1R)-1-carboxylatopentyl]-1-
[methoxycarbonyl]-D-tryptophanamide) is a modiﬁed
tripeptide developed by structure-activity analysis22 and
is a selective competitive ETB antagonist (usually showing
one to two orders of magnitude selectivity for ETB over
ETA) in human beings and across species. Because these
compounds are all peptides, they have little or no oral
bioavailability, require intra-arterial administration, and are
metabolized or excreted over comparatively short periods
of time. An advantage in their use is that they are soluble
and do not bind plasma proteins. Therefore, they are used
for short-term, acute investigations in both animal models
and in experimental medicine studies.ETA RECEPTORS PREDOMINATE ON SMOOTH
MUSCLE OF RENAL VESSELS AND MEDIATE
VASOCONSTRICTION
A major physiological action of ET-1 is to function as one
of the most powerful vasoconstrictors of human blood
vessels. As such, ET-1 plays a major role in regulating
vascular function in all organ systems, including the
kidney (Fig. 1). As in other vessels, ET-1 is thought to
be released from endothelial cells lining intrarenal vessels
throughout the cortex and medulla. In the human vascu-
lature, including that of the kidney, under normal physio-
logical conditions release of ET-1 from endothelial cells
causes sustained vasoconstriction via ETA that predom-
inate on the underlying smooth muscle. Under pathophy-
siological conditions in which ET-1 is overproduced,
vascular cells also may undergo proliferation and contrib-
ute to vascular remodeling and the development of renal
ﬁbrosis. Figure 1 shows the ratio of the densities of the two
receptor subtypes measured by radioligand binding assays
with the ETA subtype representing greater than 90% of ET
receptors in the smooth muscle layer of all renal vessels
studied. This includes the large conduit vessels, the arcuate
arteries, and veins at the corticomedullary junction, as well
as small intrarenal vessels such as the afferent and efferent
vessels of the glomerulus.23–27
In a detailed study using human isolated main stem
renal arteries and veins in organ baths,28 ET-1 was, as
expected, a potent vasoconstrictor, with the concentration
producing half-maximal response (EC50) values of 4 and
1 nmol/L, respectively. In renal artery, ET-3 and the ETB
agonist sarafotoxin 6c showed little or no activity up to
300 nmol/L. In veins, some but not all samples respondedto ET-3, but this peptide was much less potent than ET-1,
consistent with an ETA- mediated action. Interestingly, S6c
concentration-related contractions were found in some
individuals and, although more potent than ET-1, the
maximum response was 30% to 60% of that obtained with
ET-1. Crucially, however, the ETA antagonist BQ123 fully
reversed the ET-1 contractions in both arteries and veins
without reducing the maximum agonist response, consis-
tent with a competitive antagonist. Therefore, in renal
vessels the endogenous peptides ET-1 and ET-3 appear to
mediate vasoconstriction via the ETA, indicating that ETB-
mediated responses in human renal vessels are of little
importance. The pharmacology of isolated renal arteries
and veins is similar to vessels obtained from other human
vascular beds, with ETA antagonists fully reversing an ET-
1 response.29 This is critical to understanding the impor-
tance of selectivity for the two subtypes. Sarafotoxin S6c–
induced constrictor responses have been used previously as
evidence of signiﬁcant ETB constrictor responses in human
vessels. However, it is not an endogenous ligand and ET-1
responses are fully reversed using ET antagonists. Bohm
et al30 performed key experimental medicine studies that
showed in volunteers in vivo that BQ123 inhibited the ET-
1–mediated increase in renal vascular resistance whereas
BQ788 (ETB antagonist) potentiated the ET-1 effect,
implying a constrictor role for ETA and that ETB clears
ET-1 from the plasma. Kaasjager et al31 also concluded
that the systemic and renal vasoconstrictor effects of ET-1
in human beings are mediated by the ETA.
A further unusual feature of ET-1 compared with other
vasoconstrictors is that the constrictor response is sus-
tained over a considerable period of time, lasting for
several hours or in some cases several days.32 Contrac-
tions compared with many other vasoconstrictors are
slow to wash out, which is consistent with a slow
dissociation rate for ET-1 and may contribute to sus-
tained hypertension and/or ET-induced vasospasm asso-
ciated with pathophysiological conditions such as chronic
kidney disease. Importantly, ET antagonists are able to
relax ETA- mediated vasoconstriction in vessels precon-
stricted with ET-133 and this may reﬂect rapid internal-
ization of the ligand receptor complex for recycling to the
membrane (Fig. 1). In contrast, binding of ET-1 to ETB
in vivo often is not displaced by ETB antagonists,
34
which is in agreement with ETB being internalized by a
different pathway and degraded in the lysosome.HOW IMPORTANT IS THE SMALL POPULATION OF
ETB RECEPTORS EXPRESSED BY VASCULAR
SMOOTH MUSCLE?
In some, but not all, human vessels, a small population
of ETB (usually o15%) can be measured by ligand
binding. Although in some human beings isolated renal
vessel responses to high concentrations of ET-3 were
Endothelin-receptor antagonists 129detected,28 comparison of equipotent concentrations of
ET-3 and ET-1 in healthy volunteers found that ET-3
had no effect on blood pressure or renal hemodyna-
mics,31 which might have been expected if ETB
contributed signiﬁcantly to a contractile response.
Whether the proportion of vascular ETB changes with
disease remains controversial and has not been studied
in detail in pathophysiological renal tissue. However,
detailed studies in vitro in human coronary arteries
with atherosclerotic lesions did not show any
increase.35 In agreement, in experimental medicine
studies in both heart failure patients and volunteer
controls, selective ETA antagonism (BQ123) caused
the expected potent vasodilatation in the peripheral
circulation. However, BQ788 caused vasoconstriction
in both groups, consistent with blocking endothelial
cell ETB-mediated vasodilatation, with no evidence of
contractile ETB.
36,37Figure 2. Ratio of the density of human ETA and ETB measured
using radioligand binding in the whole organ (brain, kidney, lung,
liver, and heart) and measured in the medial smooth muscle layer
of the vasculature within each organ. In human beings, kidney,
lung, and liver are ETB-rich, reflecting the expression of ETB
receptors on endothelium of the vasculature and other cell types
such as the epithelium. In contrast, in the heart, ETA are the
principal subtype reflecting expression on myocytes. In the
smooth muscle layer of all human vessels, ETA are more
abundant than ETB.OTHER CELL TYPES EXPRESSING ETA RECEPTORS
ETA have been shown to be present on human and rat
podocytes (glomerular epithelial cells) that wrap around
the capillaries of the glomerulus within Bowman's
capsule.38,39 Ortmann et al40 also detected messenger
RNA encoding ETB as well as ETA on human podo-
cytes. However, ETA contribute to podocyte injury
through cytoskeleton disruption and apoptosis and only
ETA antagonists are effective in preventing podocyte
injury. In renal disease, proliferation in mesangial cells,
extracellular matrix production, and inﬂammation41,42
are mediated mainly by ETA.ETB RECEPTORS PREDOMINATE IN THE KIDNEY
AND MEDIATE BENEFICIAL VASODILATATION,
CLEARING OF ET-1 FROM PLASMA, AND
NATRIURESIS
In peripheral tissues such as the heart (Fig. 1), ETA are
more abundant (460%) than ETB (Fig. 2). In marked
contrast, in the kidney, lungs, and liver this ratio is
reversed. Although measurements of receptors within
smooth muscle throughout the renal vasculature show
a predominance of ETA, 70% of the ET receptors in
both cortex and medulla in human kidney are ETB.
ETB predominate, reﬂecting, at least in part, that these
are endothelial cell–rich tissues similar to liver and
lungs.24–26 Endothelial cells line every vessel wall and
have a mass comparable with other endocrine organs.
Although ETB also are expressed by other cell types,
selective deletion of the endothelial cell ETB, leaving
ETB on other cells intact, shows that in many organs,
including the kidney, liver, and lungs, endothelial cells
represent the majority of the receptors.43A consensus has emerged that ETB mediates vaso-
dilatation by the release of endothelium-derived relax-
ing factors (nitric oxide, prostacyclin, and/or
endothelium-derived hyperpolarizing factor), acting as
a feedback mechanism to limit the vasoconstrictor
action of ET-1. Infusions of ET-1 into the brachial
artery of volunteers produces a biphasic response: low
doses of ET-1 cause ETB-mediated vasodilatation,
however, as the concentration increases to higher
pathophysiological concentrations, vasodilatation is
overwhelmed by ETA-mediated constrictor responses.
When endothelial dysregulation occurs in renal disease
there is a loss of opposing vasodilators, leading to
increased vasoconstriction and vasospasm.
Endothelial cell ETB function as scavenging or
clearing receptors to remove ET-1 from the circula-
tion,23,43,44 particularly by the ETB-rich tissues: kid-
ney, lungs, and liver34 (Fig. 1). Selectively blocking
ETA, but not ETB, with a low dose of the peptide
antagonist TAK-044 infused into volunteers caused no
change in measured plasma ET-1 levels. However, a
higher dose that blocked both subtypes increased ET-1
J.J. Maguire and A.P. Davenport130levels by more than three-fold as a result of reducing
clearing by ETB.
45
In renal circulation, in agreement with other vascu-
lar beds in human beings, systemic infusion of ET-1,
which activates both receptors, into volunteers
increased blood pressure (6 mm Hg), and decreased
renal plasma ﬂow, glomerular ﬁltration rate, and
sodium excretion rate.31 Although BQ123 infused
alone did not affect basal arterial blood pressure or
renal or splanchnic vascular resistance, the antagonist
inhibited the increase in vascular resistance induced by
co-infusion of ET-1. In contrast, BQ788 alone caused
the opposite effect: increased renal or splanchnic
vascular resistance, consistent with blocking endothe-
lial cell–receptor vasodilatation. Second, BQ788
potentiated the ET-1–induced increase in vascular
resistance mediated by ETA, suggesting that blocking
the scavenging receptors modulated plasma ET-1
levels.30 Inhibition of tonic nitric oxide production by
inhibition of nitric oxide synthase elicits vasoconstric-
tion with an increase in mean arterial pressure and
vascular resistance in many organs, including the
kidney. Renal and systemic vasoconstriction in volun-
teers caused by the nitric oxide synthase inhibitor
N-nitro-L-arginine methyl ester were attenuated by
BQ123, supporting the concept that the balance
between endogenous nitric oxide production and ET-
1/ETA activity contributes to renal and systemic tone in
human beings.46,47
The role of ETB clearing receptors has been studied
in detail in endothelial cell–speciﬁc ETB knock-out
mice. In these animals, clearance of an intravenous
bolus of labeled ET-1 was reduced signiﬁcantly
compared with wild-type controls. Importantly, func-
tioning ETB were retained on all other cell types such
as epithelial cells.43,48 Dynamic imaging of rats using
positron emission tomography showed that after
infusion of 18F ET-1, there was remarkably fast
clearance of the radioligand from the circulation
(plasma-half life (t1/2) ¼ 0.43 min), with high levels
of radioligand accumulated in the kidney, liver, and
lung, which rapidly reached equilibrium, and this was
maintained for at least 20 minutes. Infusion of BQ788
before injecting 18F ET-1 reduced the amount of
radioligand visualized in the lung and kidney by
85% and 55%, respectively, consistent with blockade
of ETB. However, infusion of BQ788 after
18F ET-1
did not displace the bound ligand.34 This ﬁnding is
consistent with the internalization of the ligand-
receptor complex to the lysosome where ET-1 is
thought to be degraded, similar to other peptides, by
cathepsin A. In support, cathepsin A knock-out mice
showed reduced ET-1 degradation and signiﬁcantly
increased arterial blood pressure.49 Inactivation of
ET-1 by kidney, liver, and lungs may be particularly
important for ET-1 because it is structurally unusualcompared with other vasoactive peptides, possessing
two disulﬁde bridges that confer resistance to degra-
dation by nonspeciﬁc peptidases.
ET-1 promotes diuresis and natriuresis via ETB
located on epithelial cells throughout the tubular
epithelium, particularly the inner medullary collecting
duct cells.50 Deletion of ETB, but not ETA, leads to
salt-sensitive hypertension.51 In agreement, the effects
of three doses of BQ-123 (0.1, 0.2, and 0.3 mg/kg) on
renal hemodynamics, tubular function, and vasoactive
hormones were measured in volunteers in a random-
ized, placebo-controlled, double-blind, dose-response
study. The main effect was a dose-dependent increase
in renal sodium excretion despite stimulation of the
renin-angiotensin system as evidenced by an increase
in angiotensin II levels, whereas there was little effect
on atrial and brain natriuretic peptides or vasopressin.52
Goddard et al53 elegantly showed that ETA antago-
nism by BQ123 and angiotensin-converting enzyme
(ACE) inhibition using enalapril were synergistic in
reducing mean arterial pressure in volunteers. How-
ever, BQ-123 increased renal blood ﬂow, increased
urinary sodium excretion, and reduced renal vascular
resistance only during ACE inhibition. These effects
were abolished by ETB blockade using BQ788 and
nitric oxide synthase inhibition, whereas cyclooxyge-
nase inhibition had no effect. These results showed that
synergism between ETA antagonism and ACE inhibition
occurs via an ETB-mediated, nitric oxide–dependent,
cyclooxygenase-independent mechanism. In patients
with chronic kidney disease, TAK-044 beneﬁcially
reduced the mean arterial and systemic vascular resist-
ance index and tended to increase renal plasma ﬂow.
TAK-044 had no effect on sodium or lithium clear-
ance, or on the fractional excretion of sodium and
lithium.54
Combining the results from a number of different
studies has led to the proposal that antagonism of ETB
may be undesirable in conditions such as chronic renal
failure, and therefore ETA-selective antagonists might
be superior to mixed ETA/ETB antagonists. This
hypothesis was tested experimentally by comparing
the action of BQ123 or BQ788 alone or in combi-
nation in hypertensive patients with chronic renal
failure.55 Blocking the ETA alone signiﬁcantly reduced
blood pressure in these patients. The magnitude of
change was signiﬁcantly higher than when ETB also
was blocked by BQ788. BQ788 alone caused the
expected systemic and renal vasoconstriction, support-
ing the concept that ETB maintain tonic renal vaso-
dilatation in patients. BQ-123 infused alone increa-
sed renal blood ﬂow and renal vascular resistance
and reduced proteinuria, consistent with a renoprotec-
tive action. This effect was lost when ETB were
blocked by infusing both BQ788 and BQ123. There
was no change in sodium excretion but this may
Endothelin-receptor antagonists 131have been the result of a comparatively small number
of subjects.55
In a larger study of 22 patients with nondiabetic
proteinuric chronic kidney disease, BQ-123 produced
signiﬁcant natriuresis, resulting from increased renal
blood ﬂow. In addition, ETA antagonism reduced
blood pressure and proteinuria, and, a new ﬁnding,
decreased arterial stiffness.56 However, in diabetic
patients with chronic kidney disease, avosentan
(ETA-selective nonpeptide antagonist) was reported to
be detrimental as a result of ﬂuid overload.57ET-RECEPTOR BLOCKADE IN CHRONIC
KIDNEY DISEASE
Receptor antagonists have emerged as the only strategy
in the clinic for blocking the unwanted actions of ET-1.
To date, no alternative strategies, such as inhibitors of
ET converting enzymes or combined endothelin-
converting enzyme (ECE)/neutral endopeptidase
(NEP) inhibitors, have been approved. Four com-
pounds, bosentan, ambrisentan, sitaxentan, and maci-
tentan, originally were approved for clinical use in
pulmonary arterial hypertension (PAH) (Table 2).11
Sitaxentan, however, was withdrawn from clinical use
in 201058 after idiosyncratic hepatitis occurred result-
ing from acute liver failure, leading to death. PAH
affects approximately 100,000 patients in the United
States and Europe and currently there is no cure. TheTable 2. Structure and Pharmacokinetic Properties of ET-Recepto
Bosentan Macitentan
Ac
o
Trade name Tracleer (Actelion,
Allschwil,
Switzerland)
Opsumit (Actelion)
Other names Ro47-0203 ACT-064992 AC
Chemical name Benzenesulfonamide Sulfamide Sul
Structure
ET plasma levels
after
administration
↑↑ ↑↑ -
Bioavailability 50% Not reported Not
Time to maximum
plasma
concentration
3-5 4-12 30
Terminal half life
(hours)
5.4 16 40.
Excretion in urine
(%)
o3 Not detected Notdisease is characterized by constriction and remodel-
ing of pulmonary vessels, with high blood pressure in
the lungs. This leads to right heart failure, which is
the ultimate cause of death. Interestingly, although
ETA are increased signiﬁcantly in the failing right
ventricle of patients with PAH59 and the failing left
ventricle of patients with heart failure,60 clinical trails
have failed to show a beneﬁt in patients from the
latter group.12 The reasons for this are unclear, but
the action of ET antagonists on the vasculature may
be more important in restoring the imbalance
between ET-induced constriction and opposing vaso-
dilatation of blood vessels.
In theory, the selectivity of antagonists should have
pharmacologic and pathophysiological consequences.
Selectively blocking smooth muscle ETA would be
expected to lead to vasodilatation and attenuate pro-
liferation, migration, ﬁbrosis, and hypertrophy. Endo-
thelial ETB, particularly in kidney, lung, and liver,
should continue to bind and remove ET-1 where it is
overexpressed in pathophysiological conditions, as
well as releasing vasodilators to mediate their anti-
proliferative and antithrombotic actions.HOW DO WE DEFINE ANTAGONIST-RECEPTOR
SELECTIVITY?
These four antagonists represent a spectrum of selec-
tivity ranging from bosentan, which is classiﬁed by ther Antagonists in Clinical Use
tive metabolite
f macitentan Ambrisentan
Sitaxentan (withdrawn
from clinical use in 2010)
Letairis, Volibris
(Gilead, Foster
City, California)
Thelin (Pfizer, Groton,
Connecticut)
T-132577 LU-208075 TBC-11251
famide Benzenepropanoic
acid
3-Thiophenesulfonamide
↑ ↓
reported High 70%-100%
1.7-3.3 1-4
2-65.6 15 10
detected Low 50-60
J.J. Maguire and A.P. Davenport132pharmaceutical company Actelion (Allschwil, Switzer-
land) as a mixed or balanced ETA/ETB antagonist, to
sitaxentan, the most ETA selective. No consensus has
emerged about the relative merits of mixed versus
ETA-selective compounds in PAH.
61,62 Some animal
studies have suggested that selective ETA antagonism
that leaves ETB unopposed and unblocked is beneﬁ-
cial,63 whereas other studies have shown mixed and
ETA-selective antagonists have similar outcomes. The
advantage of animal studies are that compounds can be
compared head to head, but given differences in cell
expression of subtypes these may not necessarily be
informative of clinical studies in human beings. No
clear-cut advantage of one over another has been
reported for selective versus nonselective antagonism
in PAH. However, in chronic kidney disease, the
function and distribution of receptors suggests an
ETA antagonist would be preferable in blocking ETA-
mediated constriction and proliferation but sparing
endothelial cell vasodilatation, clearing ET from the
plasma, and natriuresis.64
The selectivity of a ligand for two receptors usually is
calculated by measuring the equilibrium dissociation
constant (KD) for the two subtypes, in this case ETA
and ETB, to provide a ratio of selectivity
65,66 in ligand-
binding assays. There is no standardized method or
general agreement among pharmaceutical companies to
determine which compound should be classiﬁed as ETA
selective versus a mixed antagonist.62 Accurate informa-
tion is essential in interpreting results from experiments
in animal models and clinical trials as to whether the
doses used are likely to result in a compound occupying
only ETA or both subtypes. We have proposed that ETA-
selective compounds should have at least a 100-fold
selectivity for the ETA subtype whereas mixed antago-
nists should have less than 100-fold ETA selectivity.
65
The reason for this is that the degree of receptor
occupancy achieved when an antagonist is administered
in vivo or in vitro is proportional to the concentration
and can be calculated from the afﬁnity using the
following formula: L*/(KD þ L*), where L* is the free
ligand concentration and KD is the afﬁnity constant. For
example, a compound that has an afﬁnity measured in a
ligand-binding assay of 1 nmol/L for ETA but 100 nmol/
L for ETB would have 100-fold selectivity for ETA. By
using this equation, at a concentration of 10 nmol/L,
90% of ETA are calculated to be blocked but less than
10% of the ETB. Although this concentration can be
achieved accurately under controlled in vitro conditions,
100-fold selectivity is likely to represent the minimum
that can be used in vivo to achieve selective ETA
blockade. If the plasma concentration of this antagonist
was increased to 100 nmol/L, 50% of ETB then would be
occupied. Compounds of greater than 1,000-fold selec-
tivity are likely to be needed for clinical or in vivo
studies to ensure ETA selectivity is maintained.As proof of principle, the effect of selective block-
ade was measured using TAK-044, a peptide antago-
nist with approximately 250-fold selectivity for the
ETA subtype over ETB as measured by ligand binding
in the human heart. A 30-mg infusion over 15 minutes
of TAK-044 (providing a serum concentration of
2 nmol/L, calculated to block 495% of ETA but
o5% ETB) had no effect on the immunoreactive
plasma concentrations of ET-1. However, after a
higher dose of 750 mg TAK-044 (providing a serum
concentration of 80 nmol/L, calculated to block499%
of ETA and 475% ETB), the immunoreactive plasma
ET-1 concentrations were increased more than three-
fold over basal levels. Importantly, the concentrations
of the ET-1 precursor or C-terminal fragment of big
endothelin-1 were unchanged, indicating that the
increase in ET-1 in the plasma was unlikely to be the
result of increased synthesis or release. The most likely
sources of endothelin contributing to the observed
increase were displacement of receptor-bound peptide
and a reduction in plasma clearance mediated by
ETB.
45DOES SELECTIVITY MATTER IN CHRONIC
KIDNEY DISEASE?
Blocking ETB clearly results in a signiﬁcant increase in
circulating plasma ET-1 levels. However, with a mixed
antagonist, this increase is unlikely to be important
because the vasoconstrictor ETA also is blocked. Side
effects including headache, nausea, and nasal conges-
tion have, to a certain extent, been reported for ETA/
ETB mixed antagonists and with ETA-selective com-
pounds. For ETA-selective compound such as ambri-
sentan, nasal congestion and peripheral edema are
more prevalent but they have less of the hepatic effects
such as an increase in liver enzyme levels that require
liver function tests and drug–drug interactions that are
associated with mixed antagonists such as bosentan.67
Studies in mice selectively knocking out ETA from the
nephron or collecting duct did not show ETA
antagonist-induced ﬂuid retention and this was attenu-
ated where ETA smooth muscle had been deleted,
suggesting the mechanism is a direct action on collect-
ing duct receptors and partially within the vas-
culature.68
Liver toxicity has been a signiﬁcant problem with
bosentan but its mechanism of action has been pro-
posed to be independent of ET receptors and is thought
to occur by inhibiting the bile salt export pump leading
to accumulation of cytotoxic bile salts, resulting in
hepatocellular damage. In contrast, macitentan is
thought to enter the liver via passive diffusion and
not by active uptake.69 As a result, macitentan has been
reported to have a better safety proﬁle compared with
Endothelin-receptor antagonists 133bosentan for hepatic toxicity. This is an important
consideration in patients with renal or hepatic dis-
ease.70 Bosentan is a competitive antagonist of ETA
and ETB of the sulfonamide class,
71 with a compara-
tively short half-life and good bioavailability. Bosen-
tan, as with other dual antagonists, tends to have lower
rates of ﬂuid retention and edema when used clinically.
Although bosentan has been shown to be effective in
animal models of renal disease, the compound has not
been evaluated in detailed clinical trials involving renal
patients. Ambrisentan represents the second chemical
class,71 is less ETA selective than sitaxentan, but has
good bioavailability and a long half-life. However,
again clinical studies have not been reported in chronic
kidney disease. Key clinical studies have been per-
formed using sitaxentan,71 the most ETA-selective
antagonist that largely supports the hypothesis of
selective ET blockade. A randomized, double-blind,
three-way, cross-over study of patients with proteinuric
chronic kidney disease compared sitaxentan and nife-
dipine with placebo for proteinuria, blood pressure, and
arterial stiffness. As expected, plasma levels of ET-1
were unchanged during sitaxentan treatment, indicating
that ET-1 continued to be cleared from the circulation
but urinary ET-1 levels were decreased. Blood pres-
sure, arterial stiffness, and proteinuria also were
reduced signiﬁcantly over 6 weeks. Intriguingly, asym-
metric dimethylarginine, an endogenous inhibitor of
nitric oxide synthases that is considered an independent
marker of disease progression, was increased in these
patients, supporting the concept that sparing ETB
receptors from blockade with sitaxentan treatment
would modulate the nitric oxide pathway. Importantly,
these effects were seen in patients already receiving
optimal treatment with ACE inhibitors and angiotensin
blockers. A related study also found an increase in
nocturnal dipping in blood pressure with sitaxentan.72
The results suggested that ETA antagonism had addi-
tional longer-term renoprotective effects in patients
with chronic kidney disease.73ET ANTAGONIST FOR THE FUTURE: MACITENTAN
AND ATRESENTAN
Macitentan is an insurmountable antagonist, resulting
from structure-activity studies to improve the efﬁcacy
and tolerability of bosentan, and gained approval in the
United States in 2013 for the treatment of PAH.
Actelion describes the compound as a dual antagonist,
but on the basis of their own data measuring inhibition
of [125I]–ET-1 binding to human-expressed receptors it
displays approximately 800-fold selectivity for the ETA
subtype.74 However, plasma ET-1 concentrations were
increased signiﬁcantly (two-fold at the highest dose
tested), suggesting blocking of ETB occurs at the doseused.75 A metabolite of macitentan, ACT-132577, is
active pharmacologically, albeit with a lower potency,
but reaches higher plasma concentrations and has a
longer half-life than macitentan.76–79 Key pharmacologic
parameters suggest macitentan will have the potential
for greater efﬁcacy and safety than bosentan. Maci-
tentan has a much longer receptor occupancy (17
minutes compared with 70 seconds for bosentan),
probably as a result of interaction with different amino
acid residues in the ET receptors and is an order of
magnitude more potent than bosentan, measured by
in vitro assays. Pharmacokinetic beneﬁts include fewer
interactions with other drugs, with no requirement to
alter doses in patients with renal (or hepatic) impair-
ment. Crucially, the compound has improved hepatic
safety and reduced edema/ﬂuid retention compared
with bosentan.79,80 A number of clinical trials are
actively recruiting, however, these do not yet include
chronic kidney disease patients.81
Clinical trials also recently were reported on an
investigational ETA-selective antagonist: atrasentan
(ABT 627).82 The aim of the double-blind study
performed in parallel at two centers was to determine
whether albuminuria was reduced further when atrasen-
tan was administered at two different doses, with
inhibitors of the renin-angiotensin system, to patients
with type 2 diabetic nephropathy. Atrasentan reduced
albuminuria at both doses tested, and reduced blood
pressure, cholesterol, and triglyceride levels, with
unwanted side effects being more manageable at the
lower dose. These promising results lead to the initiation
of a phase 3 multicenter trial (Study Of Diabetic
Nephropathy With Atrasentan83) with 4,000 patients.
PERSPECTIVES
After more than 25 years since the discovery of ET, the
peptide remains the most powerful and long-lasting
constrictor of the human vasculature including the
kidney described to date. In pathophysiological con-
ditions, ET-1 contributes to vascular remodeling, pro-
liferation of mesangial cells, and extracellular matrix
production mainly through binding to ETA. Beneﬁcial
actions of ET-1 on sodium and water regulation are
mainly ETB-mediated. These ﬁndings suggest an ETA-
selective antagonist would have a therapeutic advant-
age over a mixed antagonist in renal disease, and
indeed the small number of acute studies directly
comparing the peptide antagonists BQ123 versus
BQ788 suggest ETA blockade, sparing ETB, may be
beneﬁcial. However, this is balanced by the possible
greater prevalence of side effects such as edema
reported for small-molecule, orally active ETA antag-
onists compared with mixed antagonists, although the
latter also have their limitations because of liver
toxicity. In addition, head-to-head studies in patients
J.J. Maguire and A.P. Davenport134comparing orally active ETA antagonists with mixed
antagonists have not been performed. The renal ET
system remains a compelling target: will new therapies
be clinically relevant in the future? This question may
be answered by the next generation of ET antagonists.REFERENCES
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